UK's SheMed raises $50M to scale personalised women’s health for weight loss and clinical research
SheMed is also researching how weight loss treatments may benefit women’s health
SheMed, a UK-based women’s health tech company, has raised $50 million to scale its personalised healthcare platform for weight loss and expand its clinical research into the broader benefits of GLP1-s for women’s health.
Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has grown rapidly, reaching more than 60,000 members in under a year. Its most well-known programme provides access to GLP-1-based weight management treatments, supported by medical oversight and ongoing digital care.
The company is also using these treatments as part of a broader research effort. In December 2024, SheMed began a 12-month clinical study to investigate how GLP-1 medications might help manage health conditions such as PCOS, endometriosis and menopause-related symptoms - areas that remain under-researched in clinical science.
“The demand for SheMed’s services has been extraordinary,” said Chloe Ferro, Co-Founder and President of SheMed.
“Women are seeking care that recognises their individuality, their biology and their experiences. It’s why women continue to turn to SheMed for a tailored, more supportive path to healthcare.”
The new funding will be used to expand SheMed’s UK operations, strengthen its medical and technology teams, and improve clinical infrastructure. It will also back new research and patient-experience initiatives aimed at improving access to high-quality, personalised care.
SheMed has not disclosed its investors for this round.
Meeting demand
SheMed’s current model combines clinical review, digital monitoring, and continuous support through an online platform. The company says this allows for more tailored treatment plans and better access to care, addressing long-standing gaps in women’s healthcare provision.
“For more than a decade, I searched for answers to an undiagnosed health issue,” said Olivia Ferro, Co-Founder and CEO of SheMed.
“As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.”
Understanding metabolic health in women
Interest in GLP-1 medications such as semaglutide and tirzepatide has grown rapidly over the past two years. While widely used for weight management, most clinical data have not accounted for sex-based biological differences. SheMed’s study is among the first to focus on how these drugs affect women’s hormonal and metabolic responses.
Later this month, the company plans to release early findings from its research, which it says could provide new evidence to help refine treatment pathways for women.
SheMed’s research aims to bridge this gap by linking metabolic health to broader women’s health outcomes. If successful, the findings could help establish clearer clinical guidance on how GLP-1-based medications are prescribed for women with these conditions.
SheMed’s work is an example of how FemTech companies are helping to contribute to medical understanding through their own datasets and insights. Reliable, sex-specific data on the use of GLP-1 drugs remain limited, and the findings could influence both medical practice and regulatory thinking. If SheMed can demonstrate measurable benefits beyond weight management, it may help change how metabolic and hormonal health are treated together and also destigmatise the use of weight loss drugs.
The study’s first phase has closed to new participants, but data collection continues. Results are expected in early 2026, and the company plans to publish findings that could help inform how GLP-1 medications are used in women’s health.